HALB (Halberd) Short-Term Debt: $0.00 Mil (As of Jul. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Halberd Short-Term Debt?

Halberd HALB Short-Term Debt is $0.00 Mil as of Jul. 2023.

Halberd's Short-Term Debt for the quarter that ended in Jul. 2023 was $0.00 Mil.

Halberd's quarterly Short-Term Debt declined from Jul. 2008 ($0.31 Mil) to Jul. 2022 ($0.00 Mil) but then stayed the same from Jul. 2022 ($0.00 Mil) to Jul. 2023 ($0.00 Mil).

Halberd's annual Short-Term Debt declined from Jul. 2008 ($0.31 Mil) to Jul. 2022 ($0.00 Mil) but then stayed the same from Jul. 2022 ($0.00 Mil) to Jul. 2023 ($0.00 Mil).

Halberd Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Halberd Short-Term Debt Related Terms

Halberd Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Halberd's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Short-Term Debt Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Short-Term Debt
0.31 0.00 0.00

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Short-Term Debt 0.31 0.00 0.00
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.00 Mil mean?
Halberd (HALB) has a Short-Term Debt of $0.00 Mil as of Jul. 2023.
Is Halberd's Short-Term Debt too high?
Halberd's current Short-Term Debt is $0.00 Mil.
How does Halberd's Short-Term Debt compare to GRI and OCEA?
Halberd's Short-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Halberd's current Short-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halberd stock overvalued right now?
Halberd (HALB) has a current Short-Term Debt of $0.00 Mil. The current Short-Term Debt is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Halberd (HALB), the current Short-Term Debt is $0.00 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.